In RA, the reduced CTLA-4 gene transcriptional activity, due to the aforementioned epigenetic modification, prevents the activation of the IDO immune-modulatory pathway in antigen presenting cells (APCs) and, therefore, contributes to defective Treg cell function [101, 102]. This evidence concerns the gene CTLA4 and rheumatoid arthritis.